Source: Office of United States Attorneys
MIAMI – The United States has filed a complaint under the False Claims Act against AIMA Business and Medical Support, LLC (AIMA), a company that provides medical billing and compliance services, for allegedly submitting or causing the submission of false claims to Medicare for medically unnecessary genetic laboratory tests.
AIMA is registered as a Florida limited liability company and offers medical billing and compliance services in the United States. AIMA’s CEO, Aaron Liston, was based in the United Kingdom, AIMA’s employees were based in India, and AIMA provided services to customers in the United States, including billing the Medicare Program on behalf of healthcare providers and suppliers. The United States’ claims arise from AIMA’s alleged conduct in offering Medicare billing advice and submitting bills to Medicare on behalf of a Miami-based diagnostic laboratory called Excellent Laboratories Inc., which did business as Selecta Laboratory (Selecta).
The United States contends that from August 2018 through August 2019, AIMA billed Medicare Part B approximately $ 15,178,946.00 for genetic tests on behalf of Selecta, even though AIMA knew or should have known that the tests were not medically necessary and were not ordered by the beneficiary’s treating physician. Medicare does not cover the costs of genetic tests that are not reasonable and necessary for the diagnosis or treatment of illness. To be covered by Medicare, a diagnostic laboratory test, including a genetic test, must be ordered by the physician who is treating the beneficiary for a specific medical problem and who uses the results in the management of that problem. As a result of AIMA’s conduct, Selecta received Medicare funds to which it was not entitled and, correspondingly, paid AIMA for its services.
U.S. Attorney Hayden P. O’Byrne for the Southern District of Florida and Acting Special Agent in Charge Jesus Barranco of the U.S. Department of Health and Human Services, Office of Inspector General (HHS-OIG), made the announcement.
Assistant U.S. Attorney Clarissa Pinheiro is handling the matter, with the HHS-OIG conducting the investigation.
The investigation and prosecution of this matter illustrate the government’s emphasis on combating healthcare fraud. One of the most powerful tools in this effort is the False Claims Act. Tips and complaints from all sources about potential fraud, waste, abuse, and mismanagement can be reported to the HHS at 800-HHS-TIPS (800-447-8477).
The claims asserted in the government’s complaint are allegations only, and there has been no determination of liability.
You may find a copy of this press release (and any updates) on the website of the United States Attorney’s Office for the Southern District of Florida at www.usdoj.gov/usao/fls.
Related court documents and information may be found on the website of the District Court for the Southern District of Florida at www.flsd.uscourts.gov or at http://pacer.flsd.uscourts.gov, under case number 25-cv-22507.
###